| The Specialty Pharmaceuticals Market Outlook | | | | development. |
| reveals market dynamics, leading players and key | | | | • Determine therapy areas of rich opportunity |
| therapy areas of opportunity for specialty pharma | | | | which are well suited to the specialty pharma |
| companies. Market drivers include increasing | | | | business model. |
| reimbursement from national health bodies and | | | | • Develop strategies for success in the future |
| governments, industry consolidation, big pharma | | | | specialty pharma market. |
| divestments and biotech growth. Resistors | | | | Key Market Issues• Which therapy areas and |
| including increased competition, big pharma entry | | | | indications have suitable dynamics for the specialty |
| to specialty markets and the financial crisis are | | | | pharmaceutical business model? |
| also examined in the context of industry | | | | • How is the financial crisis affecting the |
| strategies of licensing deals, product acquisitions | | | | specialty pharma industry? |
| and orphan drug development. Ten leading players | | | | • Competition for licensing deals is increasing as |
| are profiled including an analysis of current | | | | big pharma companies rush to fill their pipelines. |
| products, drug pipelines and threats from patent | | | | • Healthcare reform is set to have wide |
| expiries. | | | | ranging effects on the largest pharmaceutical |
| The effects of industry trends such as rising | | | | market in the world. |
| costs, and generic erosion are analyzed and | | | | • A further round of pharma industry |
| developed into an outlook for the future of the | | | | consolidation will impact the specialty |
| specialty sector, including strategies for future | | | | pharmaceutical industry. |
| success. | | | | Key findings from this report• The specialty |
| Key features of this report | | | | pharmaceutical market is estimated at $116bn in |
| • Sizes the specialty pharmaceutical market | | | | 2010 and is forecast to grow to $141bn by 2014. |
| and makes quantitative forecasts to 2014 | | | | • In 2008, specialty pharma companies |
| • Details market drivers and resistors against | | | | accounted for 15% of global pharmaceutical sales, |
| the background of pharmaceutical market | | | | and 40% of sales not accounted for by big |
| dynamics. | | | | pharma companies. |
| • Profiles the ten largest specialty pharma | | | | • Central nervous system, anti-infectives, |
| companies, including recent deals, product pipelines | | | | cardiovascular and ophthalmology were the largest |
| and key patent expiries. | | | | specialty pharma therapy areas in 2008. |
| • Analyzes the effects of wider | | | | • Industry pressures on large diversified |
| pharmaceutical industry trends on specialty | | | | pharma companies are having a knock-on effect |
| players. | | | | on the specialty sector in the form of increased |
| • Details strategies for success in the future | | | | competition for licensing deals. |
| specialty pharma market. | | | | Key questions answered |
| Scope of this report• Assess leading players in | | | | • What is outlook for specialty pharma |
| the specialty sector. | | | | companies and therapeutic markets to 2014? |
| • Understand the drivers and resistors of the | | | | • What are the drivers and resistors of the |
| specialty pharmaceutical market. | | | | specialty pharma market? |
| • Understand key market strategies such as | | | | • What are the leading players in the specialty |
| in-licensing, acquisitions and orphan drug | | | | pharmaceutical sector? |